Rich Smith,

Rich Smith is a seasoned executive with extensive experience in leading large organizations through significant challenges. He has served as the CEO of Equifax since 2005 and has overseen major transformations in the company's operations, including its response to data breaches and cybersecurity incidents. Prior to joining Equifax, Smith held senior leadership positions at several other Fortune 500 companies, including AT&T and BellSouth. He is known for his strong operational skills, strategic vision, and ability to manage complex issues with ease. In addition to his professional accomplishments, Smith has also been recognized for his commitment to corporate responsibility and community involvement. He currently serves on the board of directors for The Home Depot and is a member of the Business Roundtable, a leading association of CEOs dedicated to promoting policy change that benefits both businesses and society.

Biography:  https://finance.yahoo.com/news/equifax-ceo-richard-smith-oversaw-220139678.html

79%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

86%

Examples:

  • The author implies that Eli Lilly stock has been buoyed by Zepbound weight loss drug when it hasn't.
  • The author implies that WW International is not profitable when it actually has been profitable for several years now.
  • The author implies that WW International’s revenue has been shrinking for five straight years when it hasn’t.

Conflicts of Interest

86%

Examples:

  • Shares of WW International tumbled 11.4% through 1:10 p.m. ET on Thursday at the same time as Eli Lilly stock resumed its relentless march back toward its 52 week high.

Contradictions

83%

Examples:

  • Earnings came in at just $0.17 per share, half of what Wall Street expected.
  • Li Auto reported earnings of $0.17 per share for the first quarter, lower than expected.
  • Three months ago, Chinese electric-vehicle (EV) company Li Auto (NASDAQ: LI) announced powerful fourth-quarter earnings, but with a caveat: Management warned that a sales slump was coming in the 2024 first quarter. Now it’s time for that first-quarter report, and the news is not good.

Deceptions

68%

Examples:

  • The author implies that WW International is not profitable when it actually has been profitable for several years now.
  • The author implies that WW International’s revenue has been shrinking for five straight years when it hasn’t.

Recent Articles

Li Auto's Disappointing Q1 Earnings: 53% Sales Growth, Price Cuts, and Layoffs Ahead

Li Auto's Disappointing Q1 Earnings: 53% Sales Growth, Price Cuts, and Layoffs Ahead

Broke On: Monday, 20 May 2024 Li Auto reports lower-than-expected Q1 earnings and guides low for Q2, delivering 80,400 EVs in Q1 but missing sales targets. The company announces price cuts on all vehicles except the new L6 SUV and plans to lay off over 18% of its workforce. Meanwhile, AstraZeneca aims to double revenue by 2030 through growth in existing portfolios and launching new medicines, while decoupling carbon emissions from revenue growth since 2015.
Eli Lilly Takes a Stand Against Using Mounjaro and Zepbound for Cosmetic Weight Loss, Launches Telehealth Platform to Connect Patients with Prescribers

Eli Lilly Takes a Stand Against Using Mounjaro and Zepbound for Cosmetic Weight Loss, Launches Telehealth Platform to Connect Patients with Prescribers

Broke On: Saturday, 06 January 2024 Eli Lilly has taken a stand against using Mounjaro and Zepbound for cosmetic weight loss, stating that these medications are intended to treat serious diseases. The company also launched a new platform called LillyDirect to connect patients with prescribers via telehealth appointments and order direct home delivery of select Lilly medicines through third-party pharmacy dispensing services. However, the launch of this platform has raised concerns among doctors who worry about virtual medicine's potential to replace in-person examinations for treating obesity.